How to Measure Glycosyltransferase Activity in Screening Campaigns for Drug Discovery

TL;DR

• Best general HTS approach (for UDP-sugar glycosyltransferases): detect UDP product using a homogeneous, mix-and-read method.
• Classic options: radiometric assays (sensitive but operationally heavy), MS/HPLC (information-rich but lower throughput), and coupled-enzyme/luminescent assays (HTS-friendly but can add interference risk).
• Transcreener® UDP² Glycosyltransferase Assay directly measures UDP formation via competitive immunodetection and supports FP, FI, and TR-FRET readouts—helpful for matching instrument availability and reducing compound interference.
• Key HTS priorities: low false positives, strong Z′, minimal coupling steps, compatibility with DMSO/automation, and a clean path to orthogonal confirmation.
• Workflow that scales: primary screen (UDP detection) → confirmation (repeat + concentration response) → orthogonal assay (different detection physics) → counterscreens for interference.

Introduction

Glycosyltransferases (GTs) catalyze the transfer of sugar moieties from activated sugar donors (often nucleotide sugars) onto acceptor substrates such as proteins, lipids, glycans, and small molecules. Because glycosylation controls protein folding, trafficking, stability, immune recognition, and signaling, GTs (and glycosylation pathways) are increasingly central to drug discovery across oncology, inflammation, infectious disease, and rare disorders.

But here’s the reality: measuring GT activity at high throughput is frequently harder than measuring kinases or proteases. Many GTs have low turnover, require membrane-associated cofactors/complexes, and use donors/acceptors that complicate detection. That’s why “assay choice” often determines whether a glycosyltransferase program scales into HTS—or stalls in optimization loops.

This guide walks through the main assay formats used to quantify GT activity in HTS campaigns, with clear pros/cons and practical decision rules. Then we’ll go deep on why nucleotide-product detection—specifically UDP detection with the Transcreener® UDP² platform—tends to be the most HTS-friendly, interference-resistant option for UDP-sugar GTs.

Why glycosyltransferases are special in drug discovery HTS

GTs sit at the center of glycobiology: they build glycans, modify proteins and lipids, and tune cell-surface identity. Dysregulated glycosylation is strongly implicated in cancer biology and immune interactions, and glycoengineering/HTS have opened new avenues for therapeutic discovery.

What makes GT assays tougher than “standard enzymes”

Common GT assay pain points include:

• Low catalytic rates (especially for human Golgi GTs), which compress signal windows.
• Complex substrates (glycoproteins, lipids, heterogeneous acceptors) that are not always amenable to labeled reporters.
• Membrane dependence for many GTs, complicating purification and buffer composition.
• Multiple donor types (UDP-, GDP-, CMP-, and others), meaning one detection chemistry often doesn’t cover everything.
• Interference sensitivity: many HTS compounds are fluorescent, redox-active, aggregators, or luciferase inhibitors—creating format-dependent false positives/negatives.

So the best GT HTS assay isn’t the fanciest—it’s the one that stays robust under compound library stress.

What you’re actually trying to measure

A glycosyltransferase reaction typically looks like:

Donor (e.g., UDP-sugar) + Acceptor → Glycosylated acceptor + Nucleotide product (e.g., UDP)

You can measure activity by quantifying:

1. Product formation on the acceptor (glycosylated product)
2. Consumption of donor (loss of UDP-sugar)
3. Formation of nucleotide byproduct (e.g., UDP release)
4. Secondary signals coupled to any of the above

In HTS, the most scalable assays usually measure the nucleotide product (especially UDP) because it’s common across many GTs and can be detected with homogeneous workflows.

Major assay formats for glycosyltransferases

Below are the most common GT activity assay families you’ll see in screening and method papers.

A) Radiometric assays (e.g., tritium/¹⁴C labeled sugars; SPA)

What it measures: transfer of radiolabeled sugar onto acceptor (direct product measurement).

Why people use it

• Extremely sensitive for low-activity enzymes
• “Direct” measurement of transfer chemistry
• Often a historical gold standard for challenging enzymes

Where it hurts in HTS

• Radioisotope handling, disposal, regulatory burden
• Operational complexity (wash steps, filtration, bead capture)
• Throughput constraints and higher cost per data point

Radiometric formats can be adapted to homogeneous detection via scintillation proximity assay (SPA), which is designed to be rapid and sensitive without separation steps, but you still inherit radioactivity logistics.

Best fit: stubborn, low-activity GTs where sensitivity is the limiting factor and operational burden is acceptable.

B) Chromatography/mass spectrometry (HPLC, LC-MS, MALDI-TOF)

What it measures: donor/acceptor/product masses or separation profiles (high information content).

Why people use it

• High confidence, structurally informative
• Great for mechanism and substrate specificity
• Excellent for confirming what product you made

Where it hurts in HTS

• Lower throughput than plate-reader methods
• Higher instrumentation complexity and per-sample cost
• Data pipelines can bottleneck in big screens

That said, MS-based approaches have been successfully adapted to high-throughput quantitative workflows (including MALDI-TOFMS screens) for certain GT targets.

Best fit: secondary confirmation, profiling, selectivity panels, or when you must verify product identity.

C) Coupled-enzyme continuous assays (spectrophotometric/fluorescent NADH readouts)

What it measures: UDP (or other nucleotide diphosphates) indirectly via coupling enzymes that consume NADH/NADPH (or related reporters).

Classic coupling logic often links nucleotide production to PK/LDH systems and monitors NADH depletion—popular because it can be continuous (kinetics in one run). Variants and “universal continuous” GT assays have been described that couple released nucleotide to reporter depletion.

Pros

• Continuous measurement (rates, not just endpoints)
• Good for enzyme characterization and MOA
• Can be plate-reader friendly

Cons

• Adds coupling enzymes (more components to inhibit/interfere with)
• Coupling can become rate-limiting or sensitive to buffer conditions
• Compound libraries can hit coupling enzymes or the reporter system (false positives)

Best fit: enzymology/characterization, kinetics, and mechanistic studies; sometimes HTS if carefully engineered with counterscreens.

D) Luminescent UDP detection (UDP converted to ATP → luciferase light)

This is a popular HTS approach: run your GT reaction, then add detection reagent that converts UDP to ATP and generates a luciferase signal proportional to UDP.

Pros

• Often highly sensitive and works across many UDP-sugar GTs
• Great instrument availability (luminometers are everywhere)

Cons / HTS caveats

• Higher false-positive risk from luciferase inhibitors, light quenchers, redox cyclers, and compounds that perturb coupled steps (a known general issue for luciferase-based readouts in screening)
• Endpoint-only (most implementations)
• Not appropriate for some complex mixtures (many vendors specify purified enzyme requirements)

Best fit: secondary screening when you have strong interference triage and orthogonal confirmation plans.

E) Direct UDP Detection Using Transcreener Assays for Glycosyltransferase HTS

Direct detection of UDP product formation using the Transcreener UDP² assay platform is one of the most HTS-ready approaches for measuring glycosyltransferase activity in drug discovery. Instead of modifying substrates or relying on enzymatic signal amplification, Transcreener assays quantify UDP released during catalysis using a competitive immunodetection strategy.

Because many therapeutically relevant glycosyltransferases use UDP-sugar donors (e.g., UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, UDP-GlcA), UDP detection provides a universal, substrate-agnostic readout that scales well across enzyme families and screening campaigns.

What It Measures

• UDP nucleotide product generated during the glycosyltransferase reaction
• Signal is proportional to enzymatic turnover, not binding or reporter displacement

The assay uses a highly selective anti-UDP antibody and a fluorescent UDP tracer. As free UDP accumulates, it competes with the tracer for antibody binding, producing a measurable signal change.

Readout Formats Available

Transcreener UDP² assays are available in multiple far-red fluorescence–based readouts, allowing teams to match detection physics to their HTS environment:

• Fluorescence Polarization (FP)
• Fluorescence Intensity (FI)
• Time-Resolved FRET (TR-FRET)

Far-red excitation/emission and (where applicable) time-resolved detection help reduce interference from compound autofluorescence and light-scattering artifacts commonly encountered in screening libraries.

Pros

• Direct measurement of catalytic activity – Measures true UDP production without modifying donors or acceptors.
• No coupling enzymes or luciferase – Eliminates additional enzymatic steps that can be inhibited by screening compounds.
• Universal for UDP-sugar glycosyltransferases – Enables platform standardization across multiple GT targets.
• Homogeneous, mix-and-read workflow – Well-suited for 384- and 1536-well HTS automation.
• Multiple detection physics options – FP, FI, and TR-FRET formats support interference triage and orthogonal confirmation.
• Effective at low percent conversion – Maintains sensitivity under conditions appropriate for competitive inhibitor discovery.

Cons

• Endpoint assay format – Not designed for continuous kinetic measurements; best paired with separate enzymology assays for MOA studies.
• Requires nucleotide background control – UDP contamination from donor stocks or enzyme preparations must be managed to preserve dynamic range.
• Limited to UDP-producing enzymes – Not applicable to glycosyltransferases that use GDP-, CMP-, or other nucleotide donors.

Best Fit

• Primary HTS for UDP-sugar glycosyltransferases
• Programs prioritizing low false-positive rates
• Screens requiring minimal assay complexity and high reproducibility
• Campaigns planning early orthogonal confirmation using alternate detection physics
• Teams standardizing assays across multiple GT targets

Comparison table (HTS decision snapshot)

A practical decision tree for picking a glycosyltransferase HTS assay

Use these questions to choose your “primary screen” format:

Step 1 — What donor nucleotide does your GT produce?

• UDP → UDP detection approaches are usually the fastest path to HTS scalability (luminescent UDP or direct UDP immunodetection).
• GDP/CMP/other → consider other nucleotide detection assays like the Transcreener GDP Assay.

Step 2 — What’s your biggest risk?

• Low activity/weak signal window → radiometric or highly sensitive nucleotide detection, plus miniaturization.
• Compound interference → choose detection physics less vulnerable to common library artifacts (often far-red fluorescence formats help), and bake in counterscreens.
• Assay complexity/throughput bottleneck → prioritize homogeneous, minimal-step, automation-friendly reads.

Step 3 — Do you need kinetics or just endpoints?

• HTS campaigns usually start with endpoints.
• If you need mechanism/kinetics, run continuous assays in characterization—not necessarily in primary screening.

Best practices for building a GT HTS assay that survives library screening

A) Control strategy

At minimum include:

• No-enzyme control (baseline nucleotide/background)
• No-substrate control (donor/acceptor background)
• Max-activity control (full reaction)
• Inhibitor control (known inhibitor if available, or EDTA/heat-inactivated enzyme where appropriate)
• DMSO control series matching your compound solvent conditions

These controls allow you to calculate:

• Z′-factor for robustness –
• Signal-to-background (S/B)
• Signal-to-noise (S/N)
• Assay drift across plates

Read More: From S/B to Z′: A Better Way to Measure Assay Quality in High-Throughput Screening

B) Manage nucleotide background early

For UDP-sugar reactions, background UDP can come from:

• donor impurity (free UDP contamination)
• donor hydrolysis during storage
• enzyme prep contaminants

Whichever detection system you choose, background nucleotide management is crucial—otherwise your dynamic range collapses and false negatives rise.

C) Miniaturize after you stabilize

A common failure mode is miniaturizing too soon. First lock:

• enzyme stability (time, temp)
• linear reaction window
• donor Km-range feasibility
• acceptable DMSO tolerance

Then go 384 → 1536 if needed.

D) Interference triage plan (design it before you screen)

Every HTS assay needs an artifact filter:

• Repeatability: re-test hits from the same stock
• Concentration response: eliminate single-point noise
• Orthogonal assay: switch detection physics (e.g., fluorescence-based UDP detection vs luminescent UDP detection vs MS confirmation)
• Counterscreen: run detection reagents without enzyme (or with UDP spike) to identify detection interference

Why UDP detection is the universal workhorse for many GT screens

Many therapeutically relevant GTs use UDP-sugar donors (UDP-Glc, UDP-Gal, UDP-GlcNAc, UDP-GalNAc, UDP-GlcA, etc.). A universal readout that detects UDP product means:

• You avoid labeled acceptors for each enzyme/substrate
• You can reuse the same detection logic across multiple GT targets
• You can compare activity across enzymes with consistent signal metrics
• You can scale quickly into HTS automation
• Both luminescent UDP detection and direct UDP immunodetection are built around this universal principle, but they differ in interference profile and workflow details.

A GT HTS workflow you can adapt (UDP-sugar example)

Phase 1 — Assay feasibility (days, not weeks)

1. Pick donor/acceptor pair that matches biology (keep acceptor simple if possible).
2. Run a time course to identify a linear window (e.g., 10% conversion).
3. Titrate enzyme to hit a signal window that preserves linearity.
4. Establish baseline donor purity/background UDP.

Phase 2 — HTS-readiness optimization

1. DMSO tolerance test (match your compound format).
2. Plate uniformity test (edge effects, incubation conditions).
3. Calculate Z′ across multiple plates (goal: robust, reproducible).

Phase 3 — Screen execution

1. Primary screen at single concentration (or qHTS if your program supports it).
2. Re-test hits + full concentration responses.
3. Add counterscreens: detection interference (UDP spike ± compound), enzyme-free background
4. Orthogonal confirmation with alternate detection physics (and LC-MS for top hits if needed).

Phase 4 — Early MOA and selectivity

• Test competition vs donor concentration (does potency shift?)
• Panel against related GTs (or unrelated UDP-producing enzymes if relevant)
• Move into cell assays aligned to glycosylation biology (cell-based screens are increasingly used to bridge in vitro to in vivo).

Why Transcreener UDP² is a top choice for HTS GT campaigns

What it is

Transcreener UDP² measures glycosyltransferase activity by detecting UDP produced by the enzyme using a competitive immunodetection approach, offered in multiple readout flavors (FP, FI, TR-FRET).

Why it tends to win in HTS practice

1) Universal for UDP-producing GTs, without coupling enzymes

A major advantage in screening is fewer moving parts. Coupled-enzyme systems can be excellent, but they introduce additional proteins that compounds can inhibit or destabilize. In contrast, Transcreener UDP² is designed to directly quantify UDP produced by the GT reaction.

2) Multiple far-red fluorescence readouts = practical interference control

Compound libraries contain fluorescent and quenching molecules, often strongest in blue/green channels. Far-red tracers and TR-FRET options can reduce risk from common autofluorescence bands and enable cleaner hit triage—especially when paired with orthogonal confirmation.

(And if you need to match instrument constraints, having FP, FI, and TR-FRET options gives you flexibility to standardize across sites and plate readers.)

3) Homogeneous, mix-and-read workflow that fits automation

For HTS, the ideal workflow is:

• run enzyme reaction
• add detection mix
• read plate

That’s exactly the operational model Transcreener UDP² is designed to support, including 384/1536 scaling.

4) Clean path to orthogonal confirmation

Even if Transcreener is your primary screen, you can confirm:

• with a different Transcreener readout mode (e.g., FP → TR-FRET)
• with luminescent UDP detection
• or with LC-MS for definitive product verification

This layered confirmation strategy is how strong HTS programs keep false positives from consuming months.

Learn more about the Transcreener UDP Glycosyltransferase Assay.

FAQs

1) What’s the easiest way to measure glycosyltransferase activity in HTS?

For many glycosyltransferases that use UDP-sugars, the easiest scalable HTS approach is to measure UDP product formation with a homogeneous mix-and-read assay (luminescent UDP detection or direct UDP immunodetection).

2) Why not just use LC-MS for everything?

LC-MS is excellent for confirming products and specificity, but it’s typically slower and harder to scale to very large compound libraries compared with plate-reader methods.

3) Are coupled-enzyme assays “bad” for GT screening?

No—coupled assays can be good for kinetics and mechanism work, but in large compound libraries they can introduce additional interference points (coupling enzymes and reporter chemistry). And they provided added steps and reagents that complicate workflows.

4) What’s the biggest cause of false positives in luminescent assays?

Many luminescent workflows rely on luciferase and multi-step coupling; compounds can inhibit luciferase, quench light, or perturb coupling chemistry—so you need counterscreens and orthogonal confirmation.

5) What makes Transcreener UDP² a strong choice for HTS?

It directly measures UDP produced by the reaction, supports multiple far-red readouts (FP/FI/TR-FRET), and is designed for homogeneous HTS workflows across UDP-sugar donors.

6) What donors does UDP-focused detection cover?

UDP detection supports GTs using common UDP-sugar donors like UDP-glucose, UDP-galactose, UDP-GlcNAc, UDP-GalNAc, UDP-xylose, UDP-glucuronic acid (among others).

References

He, M., et al. (2024). Glycosylation: mechanisms, biological functions and applications. Signal Transduction and Targeted Therapy, 9, Article 186. https://www.nature.com/articles/s41392-024-01886-1

Costa, A. F., Campos, D., Reis, C. A., & Gomes, C. (2020). Targeting glycosylation: A new road for cancer drug discovery. Trends in Cancer, 6(9), 757–766. https://www.sciencedirect.com/science/article/pii/S2405803320301291

BellBrook Labs. (n.d.). Transcreener® UDP2 Glycosyltransferase Assay Kits (Product page). https://bellbrooklabs.com/products/assays/udp-glycosyltransferase-assay-kits/

Nashed, A., & Naidoo, K. J. (2024). Universal glycosyltransferase continuous assay for uniform kinetics and inhibition database development and mechanistic studies illustrated on ST3GAL1, C1GALT1, and FUT1. ACS Omega, 9, 17518–17532. https://pubs.acs.org/doi/10.1021/acsomega.4c00485

Schimpl, M., et al. (2012). O-GlcNAc transferase invokes nucleotide sugar pyrophosphate participation in catalysis. Nature Chemical Biology, 8, 969–974. https://pmc.ncbi.nlm.nih.gov/articles/PMC3509171/

Revvity (PerkinElmer). (n.d.). Scintillation Proximity Assay (SPA). https://www.revvity.com/category/scintillation-proximity-assay-spa